



MATERIAL SAFETY DATA SHEET

Revision date: 30-Jul-2013

Version: 1.3

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Idarubicin Hydrochloride Capsules (25mg)

Trade Name:	ZAVEDOS®; Idamycin
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: White hard gelatin capsules
Signal Word: DANGER

Statement of Hazard: Fatal if swallowed.
May damage fertility or the unborn child.
Suspected of causing cancer.
Suspected of causing genetic defects.

Additional Hazard Information:

Short Term:	May cause skin irritation. (based on animal data)
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on heart, blood and blood forming organs, lymphatic system, male reproductive system, liver, kidneys, and developing fetus.

Known Clinical Effects: Bone marrow suppression is the most serious adverse effect seen during clinical use. Adverse effects most commonly reported in clinical use include effects on cardiovascular system, gastrointestinal system, liver, kidney, and skin rash. Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

EU Indication of danger: Very toxic
Toxic to Reproduction: Category 2
Carcinogenic: Category 3
Mutagenic: Category 3

EU Hazard Symbols:

MATERIAL SAFETY DATA SHEET

Material Name: Idarubicin Hydrochloride Capsules (25mg)
Revision date: 30-Jul-2013

Page 2 of 8
Version: 1.3

2. HAZARDS IDENTIFICATION

T+



EU Risk Phrases:

R28 - Very toxic if swallowed.
R40 - Limited evidence of a carcinogenic effect
R60 - May impair fertility.
R61 - May cause harm to the unborn child.
R68 - Possible risk of irreversible effects.
Hazardous Substance. Non-Dangerous Goods.

Australian Hazard Classification (NOHSC):

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Idarubicin Hydrochloride	57852-57-0	260-990-7	T+;R28 Repr.Cat.2;R60 Repr.Cat.2;R61 Carc.Cat.3;R40 Mut.Cat.3;R68	17
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Glyceryl Palmito-Stearate	None Assigned	Not Listed	Not Listed	*
Hard gelatin capsules	MIXTURE	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

MATERIAL SAFETY DATA SHEET

Material Name: Idarubicin Hydrochloride Capsules (25mg)
Revision date: 30-Jul-2013

Page 3 of 8
Version: 1.3

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release. Prevent product from entering drains.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Restrict access to work area. Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Idarubicin Hydrochloride	
Pfizer OEL TWA-8 Hr:	0.1µg/m ³
Microcrystalline cellulose	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³

MATERIAL SAFETY DATA SHEET

Material Name: Idarubicin Hydrochloride Capsules (25mg)
Revision date: 30-Jul-2013

Page 4 of 8
Version: 1.3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	2 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³

Analytical Method:	Analytical method available for idarubicin. Contact Pfizer Inc for further information.
Engineering Controls:	General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. Engineering controls should be used as the primary means to control exposures.
Environmental Exposure Controls:	Refer to specific Member State legislation for requirements under Community environmental legislation.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious, disposable gloves (double suggested) are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Capsule	Color:	White
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Chemical Stability:	Stable under normal conditions of use.
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
-----------------------------	---

Acute Toxicity: (Species, Route, End Point, Dose)

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg

MATERIAL SAFETY DATA SHEET

Material Name: Idarubicin Hydrochloride Capsules (25mg)
Revision date: 30-Jul-2013

Page 5 of 8
Version: 1.3

11. TOXICOLOGICAL INFORMATION

Rabbit Dermal LD50 > 2000 mg/kg

Idarubicin Hydrochloride

Rat Oral LD50 5.43 mg/kg

Mouse Oral LD50 13.98 mg/kg

Rat Intravenous LD50 3.08 mg/kg

Mouse Intravenous LD50 4.10 mg/kg

Rabbit Dermal LD50 > 40 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating

Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Idarubicin Hydrochloride

3 Month(s) Dog Oral 0.08 mg/kg/day NOAEL Blood forming organs, Immune system, Lymphatic system, Gastrointestinal System, Liver, Male reproductive system

13 Week(s) Rat Oral 0.192 mg/kg/day NOAEL Blood forming organs, Immune system, Lymphatic system, Kidney, Heart, Liver, Gastrointestinal system

13 Week(s) Dog Oral 0.15 mg/kg/day NOAEL Blood forming organs, Immune system, Lymphatic system, Gastrointestinal system, Liver

13 Week(s) Rat Intravenous 0.064 mg/kg/day NOAEL Blood forming organs, Immune system, Lymphatic system, Gastrointestinal system, Kidney, Heart

13 Week(s) Dog Intravenous 0.045 mg/kg/day NOAEL Blood forming organs, Immune system, Lymphatic system, Gastrointestinal system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Idarubicin Hydrochloride

Embryo / Fetal Development Rat Intravenous 0.195 mg/kg/day LOAEL Embryotoxicity, Teratogenic, Fetotoxicity

Embryo / Fetal Development Rabbit Intravenous 0.203 mg/kg/day LOAEL Not Teratogenic, Embryotoxicity, Maternal Toxicity

Fertility and Embryonic Development Rat Intravenous 0.01 mg/kg/day LOAEL Maternal Toxicity, Paternal toxicity, Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Idarubicin Hydrochloride

Bacterial Mutagenicity (Ames) *Salmonella* Positive

Mitotic Gene Conversion Not specified Positive

In Vitro Mammalian Cell Mutagenicity Hamster Positive

In Vitro Chromosome Aberration Human Lymphocytes Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Idarubicin Hydrochloride

30 Week(s) Rat Intravenous 0.06 mg/kg/month LOAEL Benign tumors, Malignant tumors

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

MATERIAL SAFETY DATA SHEET

Material Name: Idarubicin Hydrochloride Capsules (25mg)
Revision date: 30-Jul-2013

Page 6 of 8
Version: 1.3

11. TOXICOLOGICAL INFORMATION

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T+
EU Indication of danger: Very toxic
Toxic to Reproduction: Category 2
Carcinogenic: Category 3
Mutagenic: Category 3

EU Risk Phrases:
R28 - Very toxic if swallowed.
R40 - Limited evidence of a carcinogenic effect
R60 - May impair fertility.
R61 - May cause harm to the unborn child.
R68 - Possible risk of irreversible effects.

EU Safety Phrases:
S22 - Do not breathe dust.
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:
DANGER

MATERIAL SAFETY DATA SHEET

Material Name: Idarubicin Hydrochloride Capsules (25mg)
Revision date: 30-Jul-2013

Page 7 of 8
Version: 1.3

15. REGULATORY INFORMATION

Fatal if swallowed.
May damage fertility or the unborn child.
Suspected of causing cancer.
Suspected of causing genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 1, Subdivision A
Class D, Division 2, Subdivision A



Idarubicin Hydrochloride

California Proposition 65

developmental toxicity initial date 8/20/99
male reproductive toxicity initial date 8/20/99
260-990-7

EU EINECS/ELINCS List

Glyceryl Palmito-Stearate

California Proposition 65

Not Listed

Hard gelatin capsules

California Proposition 65

Not Listed

Microcrystalline cellulose

California Proposition 65

Not Listed

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present

EU EINECS/ELINCS List

232-674-9

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R28 - Very toxic if swallowed.
R40 - Limited evidence of a carcinogenic effect
R60 - May impair fertility.
R61 - May cause harm to the unborn child.
R68 - Possible risks of irreversible effects.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 7 - Handling and Storage. Updated Section 10 - Stability and Reactivity.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

MATERIAL SAFETY DATA SHEET

Material Name: Idarubicin Hydrochloride Capsules (25mg)
Revision date: 30-Jul-2013

Page 8 of 8
Version: 1.3

End of Safety Data Sheet